Amplify Weight Loss Drug & Treatment ETF THNR

Medalist Rating as of | See Amplify Investment Hub

Morningstar’s Analysis THNR

Will THNR outperform in the future?

Get our overall rating based on a fundamental assessment of the pillars below.

null Morningstar Automated Analysis

Morningstar Automated Analysis

Summary

Amplify Weight Loss Drug & Treatment ETF holds a quantitatively derived Neutral Morningstar Medalist Rating. The rating suggests the model does not express a clear expectation of outperformance or underperformance relative to peers over a full market cycle.

Rated on Published on

Unlock our full analysis with Morningstar Investor

Portfolio Holdings THNR

  • Current Portfolio Date
  • Equity Holdings
  • Bond Holdings
  • Other Holdings
  • % Assets in Top 10 Holdings 61.5
Top 10 Holdings
% Portfolio Weight
Market Value USD
Sector

Novo Nordisk AS ADR

10.18 518,276
Healthcare

Eli Lilly and Co

8.88 451,879
Healthcare

Innovent Biologics Inc

5.68 289,035
Healthcare

CSPC Pharmaceutical Group Ltd

5.45 277,524
Healthcare

Scholar Rock Holding Corp

5.30 269,967
Healthcare

Hims & Hers Health Inc Ordinary Shares - Class A

5.30 269,742
Healthcare

Regeneron Pharmaceuticals Inc

5.29 269,532
Healthcare

AbbVie Inc

5.28 268,583
Healthcare

Viking Therapeutics Inc

5.16 262,846
Healthcare

Amgen Inc

4.94 251,641
Healthcare

Sponsor Center